[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 660,326
  • Shares Outstanding, K 170,187
  • Annual Sales, $ 76,200 K
  • Annual Income, $ -17,370 K
  • EBIT $ -65 M
  • EBITDA $ -65 M
  • 60-Month Beta 2.18
  • Price/Sales 8.62
  • Price/Cash Flow N/A
  • Price/Book 2.05

Options Overview Details

View History
  • Implied Volatility 60.37% (-2.88%)
  • Historical Volatility 40.62%
  • IV Percentile 1%
  • IV Rank 1.04%
  • IV High 329.23% on 03/10/26
  • IV Low 57.55% on 05/08/26
  • Expected Move (DTE 1) 0.26 (6.73%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 316
  • Volume Avg (30-Day) 1,389
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 52,416
  • Open Int (30-Day) 56,197
  • Expected Range 3.54 to 4.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 5
  • High Estimate $-0.09
  • Low Estimate $-0.15
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.71 +2.16%
on 05/13/26
5.08 -25.39%
on 04/17/26
-0.60 (-13.67%)
since 04/13/26
3-Month
3.71 +2.16%
on 05/13/26
8.21 -53.84%
on 03/16/26
-1.53 (-28.76%)
since 02/13/26
52-Week
1.72 +120.35%
on 08/14/25
8.21 -53.84%
on 03/16/26
+1.29 (+51.60%)
since 05/13/25

Most Recent Stories

More News
CytomX Therapeutics Q1 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) executives highlighted progress across the company’s lead clinical programs and reviewed first-quarter 2026 financial results, emphasizing continued development momentum...

CTMX : 3.79 (-2.32%)
CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Therapeutics: Q1 Earnings Snapshot

CTMX : 3.79 (-2.32%)
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients...

CTMX : 3.79 (-2.32%)
CytomX Therapeutics: The Window Between Platform Promise and Commercial Reality Narrows Tomorrow

Barchart Research What to Expect from CTMX Earnings CTMX Generated May 6, 2026 Current Price $4.13 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 25.59% CytomX Therapeutics: The Window Between...

CTMX : 3.79 (-2.32%)
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 3.79 (-2.32%)
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing...

CTMX : 3.79 (-2.32%)
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has...

CTMX : 3.79 (-2.32%)
CytomX Therapeutics: Q4 Earnings Snapshot

CytomX Therapeutics: Q4 Earnings Snapshot

CTMX : 3.79 (-2.32%)
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted...

CTMX : 3.79 (-2.32%)
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

- Confirmed response rates in expansion cohorts of  32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg...

CTMX : 3.79 (-2.32%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 4.02
2nd Resistance Point 3.94
1st Resistance Point 3.87
Last Price 3.79
1st Support Level 3.71
2nd Support Level 3.63
3rd Support Level 3.56

See More

52-Week High 8.21
Fibonacci 61.8% 5.73
Fibonacci 50% 4.97
Fibonacci 38.2% 4.20
Last Price 3.79
52-Week Low 1.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.